Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease.
The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.
Age ≥19
Able to provide written, informed consent
Able to attend an in-person study visit in Omaha, NE twice a year to collect blood samples
Must also meet criteria for one specific cohort. Participants who meet criteria for more than one cohort are eligible. (The intent being that potential participants must meet the criteria for at least one cohort, but are eligible if criteria are met for more than one cohort)
Personal history of pancreatic ductal adenocarcinoma (PDAC)
Currently receiving treatment for a cancer diagnosis (excluding long-term hormonal therapy)
Pre-diabetes on metformin for ≥ 3 years
University of Nebraska
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Virginia Mason Hospital/Medical Center
Collaborator
VA Nebraska Western Iowa Health Care System
Collaborator